Potential mechanisms of resistance to venetoclax and strategies to circumvent it

Venetoclax (ABT-199), a first-in-class orally bioavailable BCL-2-selective inhibitor, was recently approved by the FDA for use in patients with 17p-deleted chronic lymphocytic leukemia who have received prior therapy. It is also being evaluated in numerous clinical trials for treating patients with various hematologic malignancies. | Potential mechanisms of resistance to venetoclax and strategies to circumvent it

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN
TÀI LIỆU MỚI ĐĂNG